Ferritin Nanocage Enables Oral GLP-1 Delivery That Works Where Standard Injection Drug Fails

Ferritin nanocages remained largely intact after 30 minutes of simulated gastric digestion and were highly resistant to intestinal proteolysis. In vivo, orally administered ferritin reached the intestinal tract without significant degradation. The GLP-1-ferritin fusion (HLG) was absorbed via TfR1-mediated endocytosis in Caco-2 monolayers. Oral HLG significantly reduced blood glucose levels and food intake in type 2 diabetic mice, while oral exenatide alone showed no such effects.

Researchers engineered a fusion protein (HLG) linking GLP-1 to the C-terminus of heteropolymer ferritin. Gastrointestinal stability was tested through simulated digestion (gastric and intestinal). In vivo stability was confirmed by tracking orally administered ferritin in mice. Cellular absorption mechanisms were studied in Caco-2 intestinal cell monolayers. Efficacy was tested in type 2 diabetic mice, comparing oral HLG against oral exenatide.

The holy grail of GLP-1 drug development is an effective oral formulation — avoiding the needles that many patients dislike. While oral semaglutide (Rybelsus) exists, it requires complex absorption enhancers and fasting. This ferritin-based approach offers a fundamentally different strategy: protect the peptide in a natural protein cage that the gut actively absorbs via existing receptor pathways. The complete failure of oral exenatide without the ferritin carrier dramatically demonstrates the technology's value.

Oral delivery of peptide drugs is arguably the most important challenge in peptide therapeutics. Ferritin nanocages offer a unique solution because they're naturally occurring proteins that the body already has mechanisms to absorb (via transferrin receptors). Unlike synthetic nanoparticles, ferritin is biocompatible and non-immunogenic. This platform could potentially deliver not just GLP-1 but any therapeutic peptide that currently requires injection — insulin, parathyroid hormone, calcitonin — potentially transforming chronic disease management for millions of patients.

This is a preclinical mouse study. The diabetic mouse model may not predict human oral bioavailability. The fusion protein manufacturing complexity and scale-up feasibility were not addressed. Long-term safety of repeated oral ferritin nanocage administration is unknown. Comparison was against free exenatide, not against the engineered oral semaglutide formulation that uses absorption enhancers. Dosing relative to injectable GLP-1 drugs was not quantified.